The cadence of vaccine production has arguably never been more in the spotlight. Over the last few years, a global pandemic caused by the COVID-19 outbreak sparked public outcries for vaccines quicker than manufacturers were initially able to develop, produce and distribute them.
And while COVID-19 has now entered an endemic stage in most regions of the world, it likely won’t be the last disease that affects the global population. Just this past spring, the World Health Organization declared the monkeypox outbreak as a “public-health emergency of international concern.”
In turn, this will continue to place a greater emphasis on getting future vaccines to market in a much quicker timeframe, with scalability representing a focal point.


